The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15 billion in 2015 to nearly $20 billion by 2025. The prevalence of COPD increases as populations age, and this increase is coupled with a rising diagnosis rate as efforts to promote awareness of the disease continue and the use of spirometry to diagnose COPD becomes more widespread. The expanding COPD patient population has great unmet need because truly disease-modifying therapies are lacking. Currently, treatment is dominated by bronchodilators that help alleviate symptoms but do not reverse the progression of the disease. Polypharmacy is common, especially among the severe to very severe patient population, and therapies that offer incremental improvements over existing treatment will gain use because they alleviate some of the burden associated with complex regimens. The mild to moderate patient population, especially, will benefit from increased access to certain drugs, as several generic therapies are anticipated to launch in the coming years. Despite generic/branded-generic entry of several leading inhaled therapies, major-market COPD sales will grow steadily over our forecast period owing to the uptake of current and future fixed-dose combinations in both subpopulations, and an increasing drug-treated population.


Related Reports

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2020

The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) tow...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details